NCT03803007View on ClinicalTrials.gov

Acute Ischemic Stroke Interventional Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 6, 2019

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Intravenous ACT017 1000 mg

Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms

OTHER

Intravenous Placebo

Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms

Trial Locations (1)

33404

Centre Hospitalier Universitaire de Bordeaux,, Bordeau

Sponsors

Lead Sponsor

Acticor Biotech
All Listed Sponsors
lead

Acticor Biotech

INDUSTRY

NCT03803007 - Acute Ischemic Stroke Interventional Study | Biotech Hunter | Biotech Hunter